Search clinical trials for: Raltegravir (Isentress®)

Total 13936 results

IrsiCaixa

Completed

Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors

HIV-1 Infection

Spain
Kristine Patterson, MD
Merck Sharp & Dohme LLC

Completed

A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women

HIV | AIDS

United States
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen) (WIP)

HIV-1 Infection
ANRS, Emerging Infectious Diseases

Completed

Evaluation of Raltegravir During the Third Trimester of Pregnancy (ANRS 160 RalFE)

HIV-1 Infection | PREGNANCY

France
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

Human Immunodeficiency Virus (HIV) Infection

Japan
University of North Carolina, Chapel Hill
Merck Sharp & Dohme LLC

Completed

Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults

Human Immunodeficiency Virus

United States
Gilead Sciences

Completed

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

HIV Infection

Canada, Germany, United States, Spain, France, Australia, Puerto Rico, Italy, Belgium, Mexico, Switzerland, Portugal, Netherlands, United Kingdom
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA) (GRAPPA)

HIV Infections

Netherlands
Merck Sharp & Dohme LLC
Covance

Completed

A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)

HIV Infection
Massachusetts General Hospital
Merck Sharp & Dohme LLC

Completed

Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

HIV | Neurotoxicity | HIV-associated Neurocognitive Disorder

United States
Centre Hospitalier Intercommunal de Toulon La Seyne...
Merck Sharp & Dohme LLC; Abbott

Completed

IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients (IntensVIH)

HIV Infections

France
ANRS, Emerging Infectious Diseases
Janssen-Cilag Ltd.

Terminated

Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

Viremia | HIV-1 Infection | Treatment Resistant Disorders

France
Merck Sharp & Dohme LLC

Completed

Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138) (RACING)

HIV Infections
Central Institute of Epidemiology, Moscow, Russia
Merck Sharp & Dohme LLC

Unknown

Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients

HIV Infections | Tuberculosis

Russian Federation
Queen Mary University of London
Merck Sharp & Dohme LLC

Completed

Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis (INSPIRE)

Relapsing Remitting Multiple Sclerosis

United Kingdom
The Miriam Hospital
Merck Sharp & Dohme LLC; Tufts Medical Center

Completed

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

HIV Infections | HIV | Hypertriglyceridemia | Hyperlipidemia

United States
University of California, Los Angeles
University Health Network, Toronto; Merck Sharp & Dohme LLC; Tufts University; Vanderbilt... and other collaborators

Completed

Raltegravir Therapy for Women With HIV and Fat Accumulation

HIV Infections | Lipodystrophy

United States, Canada
Stanford University

Completed

RAL-eve Study: Raltegravir Substitution Study

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

HIV Infections

United States, Puerto Rico, South Africa, Argentina, Brazil, Botswana
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC

Completed

Renal Transplantation and Raltegravir in HIV-Infected Patients (ANRS153TREVE)

HIV-1 Infection | Chronic Renal Insufficiency

France
St Vincent's Hospital, Sydney
Merck Sharp & Dohme LLC

Terminated

A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV (HANDral)

Human Immunodeficiency Virus (HIV) | HIV Associated Neurocognitive Disorders (HAND)

Australia
UMC Utrecht
Merck Sharp & Dohme LLC

Unknown

RAltegravir Switch STudy: Effects on Endothelial Recovery (RASSTER)

HIV Infection | Endothelial Dysfunction

Netherlands
University of North Carolina, Chapel Hill

Completed

Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.

Pharmacokinetics

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection

HIV Infections

United States, Thailand, Puerto Rico, Brazil, South Africa
University of Zurich
Merck Sharp & Dohme LLC; Swiss HIV Cohort Study

Completed

Raltegravir in the Swiss HIV Cohort Study

HIV Infection

Switzerland
University of Washington
Merck Sharp & Dohme LLC

Completed

Levels of Raltegravir in the Female Genital Tissue

HIV

United States
University of California, San Francisco
National Institute of Mental Health (NIMH); Merck Sharp & Dohme LLC

Completed

Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients

HIV Infections

United States
Kaiser Permanente
Merck Sharp & Dohme LLC

Completed

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects (CHEER)

HIV Infections

United States
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir (OPAL)

HIV Infections | HCV Infections

Netherlands
Merck Sharp & Dohme LLC

Completed

A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)

Human Immunodeficiency Virus
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)

HIV Infections
Lin, Hsi-Hsun, M.D.

Completed

Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study (TaISENWITCH)

HIV Infection | Quality of Life | Adverse Drug Reaction

Taiwan
Hospital Clinic of Barcelona

Unknown

Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers (RALMET-VOLHCB)

Healthy Volunteers

Spain
Changi General Hospital
National University Hospital, Singapore; Merck Sharp & Dohme LLC

Completed

Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers

Human Immunodeficiency Virus

Singapore
Helsinki University Central Hospital
Merck Sharp & Dohme LLC

Completed

Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir (OBERAL)

Fatty Liver | Metabolic Syndrome | HIV Seropositivity

Finland
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC

Completed

Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients (LIVERAL)

Liver Failure | HIV Infection | Evidence of Liver Transplantation

France
Angela Kashuba, PharmD
Merck Sharp & Dohme LLC

Completed

Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers

Healthy Volunteer

United States
St Vincent's Hospital, Sydney
Merck Sharp & Dohme LLC; The Alfred; Holdsworth House Medical Practice

Completed

Switch From Tenofovir to Raltegravir for Low Bone Mineral Density (TROP)

HIV Infections | HIV | Osteoporosis | Osteopenia

Australia
Merck Sharp & Dohme LLC

Approved for marketing

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

HIV Infections
Groupe d'Etude sur le Risque d'Exposition des Soignants...
Merck Sharp & Dohme LLC

Completed

Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection

HIV Infections

France
The University of Texas Health Science Center,...

Unknown

A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas

HIV Infection

United States
National Jewish Health
Merck Sharp & Dohme LLC

Completed

Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen

HIV

United States
University of Nebraska

Completed

Measurement of Plasma and Intracellular Concentrations of Raltegravir

HIV

United States
University of Washington
Merck Sharp & Dohme LLC

Terminated

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1 (UW PIC 330)

Human Immunodeficiency Virus

United States
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation (RAPID)

HIV
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)

HIV Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

HIV Infections
McGill University Health Centre/Research Institute...
Merck Sharp & Dohme LLC

Completed

Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients

Fatty Liver | HIV | Nonalcoholic Steatohepatitis

Canada
Yale University
National Institute on Drug Abuse (NIDA); Merck Sharp & Dohme LLC

Completed

Buprenorphine/Raltegravir Pharmacokinetic Interaction Study

HIV Infections | HIV Infection

United States
University of Colorado, Denver

Completed

Effect of Antacids on the Pharmacokinetics of Raltegravir

HIV Infections

United States

Search clinical trials for: Raltegravir (Isentress®)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations